Ion channel dysfunctions lead to a wide array of illnesses including epilepsy, cardiac arrhythmia and type II diabetes. However, the number of clinically approved drugs for restoring normal ion channel function is limited.
Neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) have been characterized by the expansion of the GGGGCC hexanucleotide repeat within the non-coding region of the human chromosome 9 open reading frame 72 (C9ORF72) gene.
Stanford researchers in the laboratory of Dr. Daria Mochly-Rosen have developed novel small molecules for modulating ALDH2 (mitochondrial aldehyde dehydrogenase-2).
Stanford researchers developed a first-in-class small-molecule inhibitor of the CLC-2 ion channel for research and drug development. CLC-2 is part of the CLC family of chloride ion channels, which regulate the flux of chloride ions across cell membranes.
Stanford researchers have identified lipid droplet accumulating microglia (LAM) in aging brains, proposing that these microglia play a role in neurodegenerative disease.
Stanford researchers have developed a molecular diagnostic for Alzheimer's disease (AD) based on their recent discovery of an immunologic signature. While innate inflammation has been implicated in AD, little is known about the role of the adaptive immune response.
Stanford researchers have designed a frequency-multiplexed neural probe architecture that enables massive scaling of electrophysiological recording from neurons.
Stanford researchers have designed a non-invasive, low power ultrasonic neuromodulation device which can target tissue deep in the brain with high spatial-temporal resolution.
Researchers at Stanford have developed a combination therapy to treat neuroblastoma, the most common and deadly solid tumor in childhood. Neuroblastoma derives from neural crest cells that fail to exit the cell cycle and differentiate.
Engineers at the Khuri-Yakub Group have designed a non-surgical alternative for treating epilepsy using ultrasonic technology which can detect, localize, and suppress epileptic seizures in epileptic patients.
Summary: Stanford researchers at the Melosh Lab have proposed a non-invasive, high electrode density, high resolution (100 micrometers to 10 nanometers) neural device implantation for electrical stimulation of neural/biological tissues.
Researchers in Dr. Michelle Monje-Deisseroth's lab at Stanford have recently identified therapeutic targets for drug development to limit the spread of high-grade gliomas (HGGs).